Positive results for NA-1 (NoNo) in Phase II Trial of Stroke patients

Final results of the ENACT Phase II clinical trial of the drug, NA-1 (TAT-NR2B9c) for reducing Stroke damage, from NoNo Inc, have been presented. The ENACT trial was a 185-patient, randomized, double-blind placebo-controlled study performed to assess the safety and efficacy of NA-1 in reducing small embolic strokes in patients that underwent an endovascular repair of intracranial Aneurysms. Patients enrolled in ENACT included individuals who had suffered a brain hemorrhage, in order to evaluate the safety of NA-1 in both ischemic and hemorrhagic Strokes. NA-1 belongs to a class of drugs termed PSD-95 inhibitors, which disrupt pro-death signaling pathways that involve the postsynaptic density-95 (PSD-95) protein found in neuronal synapses. Based upon the favourable results presented, NoNO intends to initiate later stage clinical trials in multiple Stroke indications including acute ischemic Stroke and subarachnoid haemorrhage. Additionally, NA-1 has been granted Fast-Track Designation by the FDA for the reduction of procedurally induced strokes and cognitive impairment in patients undergoing endovascular repair of brain aneurysms. The data was presented at the International Stroke Conference in New Orleans on February 2, 2012.